EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma

Maria De Luca iD, Francesco Balestra iD, Giorgia Panzetta, Gianluigi Giannelli iD, Maria Principia Scavo iD

Cells · 2026

DOI: 10.3390/cells15181637 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Maria De Luca und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS de Bellis, Via Turi 27, Castellana Grotte, 70013 Bari, Italy. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Biomarkers, Tumor, Pancreatic Neoplasms, Stromal Cells. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, partly because its dense, heterogeneous stroma restricts drug delivery, promotes immune exclusion, and supports therapeutic resistance. Stromal targeting has, therefore, evolved from broad depletion towards biomarker-guided reprogramming and normalization strategies that aim to restore vascular function, improve intratumoral drug penetration, and enhance antitumor immunity. This review summarizes evidence on stromal biomarkers with prognostic or predictive value, including tumor–stroma ratio, fibrosis burden, cancer-associated fibroblast states, extracellular matrix stiffness, vascular accessibility, and spatial immune features. It also examines emerging therapeutic approaches to reprogram the PDAC stroma, such as repurposed drugs, immune–stromal modulators, metabolic interventions, and advanced delivery systems. Emphasis is placed on clinically or translationally supported strategies, including CXCR4, CD40, CD73, vitamin D receptor agonism, matrix remodeling, and biomarker-driven stratification. Overall, PDAC stroma is a dynamic therapeutic target, requiring composite biomarkers and rational combinations with chemotherapy, immunotherapy, and delivery-enhancing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalBiomarkers, TumorPancreatic NeoplasmsStromal CellsCellular ReprogrammingHumansTumor MicroenvironmentAnimalsExtracellular MatrixCancer-Associated Fibroblasts

Stichwörter der Autor:innen

biomarkerscancer-associated fibroblastsextracellular matrixpancreatic ductal adenocarcinomastromal reprogrammingtumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS de Bellis, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
  • Scientific Direction, National Institute of Gastroenterology IRCCS de Bellis, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.

ORCID-Profile: Maria De Luca, Francesco Balestra, Gianluigi Giannelli, Maria Principia Scavo

Förderung

  • Ministero della Salute
  • Italian Ministry of Health

Zitieren

APA

De Luca, M., Balestra, F., Panzetta, G., Giannelli, G., & Scavo, M. P. (2026). Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma. Cells. https://doi.org/10.3390/cells15181637

Vancouver

De Luca M, Balestra F, Panzetta G, Giannelli G, Scavo MP. Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma. Cells. 2026. doi:10.3390/cells15181637

BibTeX
@article{DeLuca2026,
  author = {De Luca, Maria and Balestra, Francesco and Panzetta, Giorgia and Giannelli, Gianluigi and Scavo, Maria Principia},
  title = {Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15181637}
}
Kostenlos starten →